FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
FibroBiologics (Nasdaq: FBLG) has announced a breakthrough in neurodegenerative disease research through their Cuprizone animal model study. The research demonstrated that intravenous fibroblasts can significantly increase myelin expression within seven weeks using both single and multiple dose treatments.
This finding confirms their previous results from the Experimental Autoimmune Encephalomyelitis (EAE) animal model. The research focuses on myelin sheath regeneration, which is important for proper nerve function and often damaged in conditions like multiple sclerosis. The myelin sheath is essential for rapid neural communication, affecting functions such as thinking, memory, movement, and coordination.
The company, which holds 240+ patents issued and pending for fibroblast-based therapeutics, aims to develop treatments that address the root causes of chronic diseases rather than just symptoms.
FibroBiologics (Nasdaq: FBLG) ha annunciato una scoperta nel campo della ricerca sulle malattie neurodegenerative attraverso il loro studio sul modello animale di Cuprizone. La ricerca ha dimostrato che i fibroblasti somministrati per via endovenosa possono aumentare significativamente l'espressione di mielina entro sette settimane, utilizzando sia trattamenti a dose singola che multipla.
Questa scoperta conferma i loro risultati precedenti dal modello animale di Encefalomielite Autoimmune Esperimentale (EAE). La ricerca si concentra sulla rigenerazione della guaina mielinica, che è importante per il corretto funzionamento dei nervi e spesso danneggiata in condizioni come la sclerosi multipla. La guaina mielinica è essenziale per una comunicazione neurale rapida, influenzando funzioni come il pensiero, la memoria, il movimento e la coordinazione.
L'azienda, che detiene oltre 240 brevetti concessi e in attesa per terapie basate su fibroblasti, mira a sviluppare trattamenti che affrontino le cause profonde delle malattie croniche piuttosto che solo i sintomi.
FibroBiologics (Nasdaq: FBLG) ha anunciado un avance en la investigación de enfermedades neurodegenerativas a través de su estudio con el modelo animal de Cuprizone. La investigación demostró que los fibroblastos administrados por vía intravenosa pueden aumentar significativamente la expresión de mielina en un plazo de siete semanas, utilizando tanto tratamientos de dosis única como múltiple.
Este hallazgo confirma sus resultados anteriores del modelo animal de Encefalomielitis Autoinmune Experimental (EAE). La investigación se centra en la regeneración de la vaina de mielina, que es importante para el correcto funcionamiento de los nervios y a menudo se daña en condiciones como la esclerosis múltiple. La vaina de mielina es esencial para una comunicación neural rápida, afectando funciones como el pensamiento, la memoria, el movimiento y la coordinación.
La empresa, que posee más de 240 patentes emitidas y pendientes para terapias basadas en fibroblastos, tiene como objetivo desarrollar tratamientos que aborden las causas fundamentales de las enfermedades crónicas en lugar de solo los síntomas.
FibroBiologics (Nasdaq: FBLG)는 Cuprizone 동물 모델 연구를 통해 신경퇴행성 질환 연구에서 획기적인 발견을 발표했습니다. 연구 결과, 정맥 주사로 투여된 섬유아세포가 7주 이내에 단일 및 다회 투여를 통해 수초의 발현을 유의미하게 증가시킬 수 있음을 보여주었습니다.
이 발견은 실험적 자가면역 뇌척수염(EAE) 동물 모델에서의 이전 결과를 확인합니다. 연구는 수초 재생에 중점을 두고 있으며, 이는 신경 기능에 중요하고 다발성 경화증과 같은 상태에서 종종 손상됩니다. 수초는 빠른 신경 통신에 필수적이며, 사고, 기억, 움직임 및 협응과 같은 기능에 영향을 미칩니다.
240개 이상의 섬유아세포 기반 치료제에 대한 특허를 보유한 이 회사는 단순히 증상이 아닌 만성 질환의 근본 원인을 다루는 치료제를 개발하는 것을 목표로 하고 있습니다.
FibroBiologics (Nasdaq: FBLG) a annoncé une avancée dans la recherche sur les maladies neurodégénératives grâce à leur étude sur le modèle animal de Cuprizone. La recherche a démontré que les fibroblastes administrés par voie intraveineuse peuvent augmenter de manière significative l'expression de la myéline en sept semaines grâce à des traitements à dose unique et multiple.
Cette découverte confirme leurs résultats précédents issus du modèle animal de l'Encéphalomyélite Auto-immune Expérimentale (EAE). La recherche se concentre sur la régénération de la gaine de myéline, qui est essentielle pour le bon fonctionnement des nerfs et souvent endommagée dans des conditions telles que la sclérose en plaques. La gaine de myéline est cruciale pour une communication neuronale rapide, affectant des fonctions telles que la pensée, la mémoire, le mouvement et la coordination.
L'entreprise, qui détient plus de 240 brevets délivrés et en attente pour des thérapies basées sur les fibroblastes, vise à développer des traitements qui s'attaquent aux causes profondes des maladies chroniques plutôt qu'à leurs seuls symptômes.
FibroBiologics (Nasdaq: FBLG) hat einen Durchbruch in der Forschung zu neurodegenerativen Erkrankungen durch ihre Cuprizone-Tiermodellstudie bekannt gegeben. Die Forschung zeigte, dass intravenös verabreichte Fibroblasten die Myelinexpression innerhalb von sieben Wochen erheblich steigern können, sowohl bei Einzel- als auch bei Mehrfachdosen.
Diese Erkenntnis bestätigt ihre vorherigen Ergebnisse aus dem Tiermodell der experimentellen autoimmunen Enzephalomyelitis (EAE). Die Forschung konzentriert sich auf die Regeneration der Myelinschicht, die für die ordnungsgemäße Nervenfunktion wichtig ist und häufig bei Erkrankungen wie Multipler Sklerose beschädigt wird. Die Myelinschicht ist entscheidend für eine schnelle neuronale Kommunikation und beeinflusst Funktionen wie Denken, Gedächtnis, Bewegung und Koordination.
Das Unternehmen, das über 240 erteilte und anhängige Patente für fibroblast-basierte Therapeutika hält, hat das Ziel, Behandlungen zu entwickeln, die die Ursachen chronischer Krankheiten ansprechen, anstatt nur die Symptome zu behandeln.
- Successful demonstration of myelin regeneration in second animal model validates previous research
- Statistically significant increase in myelin expression achieved within 7 weeks
- Strong intellectual property portfolio with 240+ patents issued and pending
- Research still in preclinical stage with no human trial data
- Forward-looking statements indicate risks related to company's liquidity and capital resources
- Unpredictable relationship between preclinical results and clinical study outcomes
Insights
FibroBiologics' announcement represents a significant scientific milestone in their development of fibroblast-based therapies for neurodegenerative diseases. The confirmation of remyelination capability in a second validated animal model (Cuprizone) strengthens the scientific validity of their approach, as reproducibility across different models substantially reduces the risk of model-specific findings.
The statistically significant increase in myelin expression within seven weeks following both single and multiple dose fibroblast treatments is particularly noteworthy. For a clinical-stage biotech with a modest
FibroBiologics' extensive intellectual property portfolio (240+ patents issued and pending) provides substantial competitive protection for their fibroblast platform technology. Their focus on addressing root causes rather than symptoms represents a potentially disruptive approach in the neurodegenerative disease space.
However, investors should recognize this remains early-stage research with considerable development hurdles ahead. The translation from animal models to human clinical efficacy is notoriously challenging in neurodegenerative diseases. The company will need to demonstrate safety, optimal dosing, delivery mechanisms, and ultimately clinical efficacy before commercialization becomes feasible. This announcement represents scientific progress but exists within a lengthy development timeline typical for novel biologics.
The remyelination results demonstrated by FibroBiologics carry substantial scientific significance in the field of neurodegenerative disease research. Demyelination – the loss of the protective myelin sheath around nerve fibers – is a fundamental pathological process in multiple sclerosis and several other neurological conditions. The ability to restore this myelin represents one of the holy grails in neurodegenerative research.
What makes this announcement particularly interesting is the demonstration of efficacy across two distinct animal models (Cuprizone and EAE). These models simulate different aspects of demyelinating diseases; Cuprizone induces toxin-mediated demyelination while EAE mimics the autoimmune component. Success in both models suggests fibroblasts may address multiple pathological mechanisms of demyelination.
The intravenous administration route is also noteworthy, as it suggests these cells can effectively cross the blood-brain barrier to exert their effects – a significant challenge in neurological therapeutics. The observed remyelination within seven weeks indicates relatively rapid biological activity.
While promising, critical questions remain about the mechanism of action, durability of remyelination, functional recovery correlation, and immune tolerance in humans. The potential clinical implications are substantial if these preclinical results translate to humans, as current MS therapies primarily focus on preventing further damage rather than repairing existing neurological deficits.
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a significant advancement in neurodegenerative disease research. Leveraging the well-established Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblasts can facilitate remyelination.
FibroBiologics’ Cuprizone animal model study demonstrated a statistically significant increase in myelin expression within seven weeks after both single and multiple dose fibroblast treatments. This confirms FibroBiologics’ previous report of remyelination with the Experimental Autoimmune Encephalomyelitis (EAE) animal model. Myelin sheath, the insulating layer around nerve fibers, is critical for proper nerve function and is often damaged in neurodegenerative diseases like multiple sclerosis. In the brain, the myelin sheath plays a critical role in speeding up communications between neurons. This is especially important in the brain, where rapid and precise signaling is needed for functions like thinking, memory, movement, and coordination.
“This confirmation by our talented team of researchers demonstrates that fibroblasts can support the regeneration of myelin sheath, marking a potentially significant step in the utilization of a cell-based therapeutic in regenerative medicine,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.
“Our team’s findings advance our understanding of fibroblasts’ regenerative capabilities,” said Pete O'Heeron, Founder & Chief Executive Officer of FibroBiologics. “Confirming remyelination in a second validated animal model is an important step in our research and development efforts, offering fresh hope for patients with demyelinating diseases, including multiple sclerosis. These findings advance our mission to develop transformative fibroblast-based therapies that address the root causes of chronic disease, not just their symptoms, and reflect our dedication to pushing the frontiers of regenerative medicine."
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of fibroblasts to facilitate remyelination and to address demyelinating diseases, including multiple sclerosis. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What breakthrough did FBLG announce in their April 2025 research?
How does FBLG's remyelination research impact multiple sclerosis treatment?
What are the key findings of FBLG's Cuprizone model study in 2025?
How many patents does FibroBiologics (FBLG) currently hold?
What validation supports FBLG's remyelination research findings?
